High prevalence of genetic diseases in infants is expected to drive the growth of the global prenatal and newborn genetic testing market
According to a new market research study titled prenatal and newborn genetic testing market - Global Analysis and Forecasts by Product, Disease Indication, and End User. The global prenatal and newborn genetic testing market is expected to reach US$ 11,204.7 Mn in 2027 from US$ 4,034.4 in 2018. The market is estimated to grow with a CAGR of 12.2% from 2019-2027. The report highlights the trends prevalent in the global prenatal and newborn genetic testing market and the factors driving the market along with those that act as deterrents to its growth. Key factors driving the growth of the market are a high prevalence of genetic diseases in infants, support from government to promote prenatal and newborn genetic test, and increase the birth rate in various countries across the globe. However, risk associated prenatal genetic tests are likely to pose a negative impact on market growth.
Several types of genetic diseases affect the fetuses in the womb. The way in which these genetic diseases are inherited helps to determine the risk that they pose on pregnancy as well as the risk of its recurrence. The risk of having genetic diseases in babies is high in cases where the parents have another child with a genetic disease, family history of a genetic disorder, or if either of a parent has a chromosomal abnormality. There is a significant prevalence of genetic diseases among infants. Moreover, these diseases are also responsible for infant mortality across the globe. For instance, according to the World Health Organization 2016, an estimated 7.9 million infants across the world are born with genetic defects. Moreover, according to the Centers for Disease Control and Prevention (CDC), birth defects affects every 1 in 33 babies born in the US. On the other hand, chromosomal abnormalities such as Down syndrome affects 1 in 691 babies born in the US, as per the CDC’s data in 2017. Thus, the high prevalence of genetic diseases among infants account for the increasing demands for prenatal and newborn genetic tests, thereby contributing to the growth of the market.
The global prenatal and newborn genetic testing market, based on the disease indication was segmented into cystic fibrosis, sickle cell anemia, Down syndrome, phenylketonuria, and other diseases. In 2018, Down syndrome segment held the largest share of the market, by disease indication. The highest share of Down syndrome attributes to the high prevalence of this genetic abnormality among fetuses and the availability of multiple tests for its screening and diagnostics. However, the cystic fibrosis segment is expected to grow at the fastest rate during the coming year.
Some of the prominent players operating in prenatal and newborn genetic testing market are, Abbott, Quest Diagnostics Incorporated, Ravgen, Bio-Rad Laboratories, Inc., Illumina, Inc., F. Hoffmann La-Roche Ltd., Qiagen, Berry Gene, PerkinElmer, Inc., Natera, Inc., and Laboratory Corporation of America Holdings (Sequenom) among others. The market players are focused on bringing new and innovative products and services to sustain their position in the market. For instance, In April 2017, Illumina announced the introduction of VeriSeq NIPT Solution, an NGS based approach to non-invasive prenatal testing in the European Union. The company aims to expand its product offering and revenue generation from the European region with this launch. The developments performed by the companies are likely to help the market to grow in the coming years.
The report segments the global prenatal and newborn genetic testing market as follows:
Global Prenatal and Newborn Genetic Testing Market – By Product
Global Prenatal and Newborn Genetic Testing Market – By Disease Indication
Global Prenatal and Newborn Genetic Testing Market – By End User
Global Prenatal and Newborn Genetic Testing market – By Geography
Contact Person: Sameer Joshi
Email Id: email@example.com